Vaxart (NASDAQ:VXRT) Shares Cross Below 200 Day Moving Average – Time to Sell?

Vaxart, Inc. (NASDAQ:VXRT) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.73 and traded as low as $0.72. Vaxart shares last traded at $0.74, with a volume of 1,361,347 shares.

Vaxart Trading Down 0.2 %

The stock has a fifty day simple moving average of $0.66 and a two-hundred day simple moving average of $0.73. The firm has a market cap of $168.34 million, a PE ratio of -1.80 and a beta of 0.62.

Hedge Funds Weigh In On Vaxart

Several hedge funds have recently bought and sold shares of the company. Mesirow Financial Investment Management Inc. boosted its holdings in Vaxart by 100.0% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 20,000 shares during the period. XTX Topco Ltd raised its position in shares of Vaxart by 869.3% in the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock worth $116,000 after buying an additional 122,387 shares in the last quarter. Geode Capital Management LLC boosted its stake in Vaxart by 15.8% during the third quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company’s stock valued at $2,160,000 after buying an additional 346,725 shares during the period. Finally, Millennium Management LLC grew its position in Vaxart by 110.8% during the second quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company’s stock worth $2,660,000 after buying an additional 2,095,274 shares in the last quarter. Hedge funds and other institutional investors own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.